Perioperative toripalimab combined with chemotherapy significantly reduces surgery cancellation rates in patients with stage III resectable NSCLC.
Improved tumor and lymph node downstaging rates with toripalimab are strongly associated with enhanced event-free survival (EFS).
Perioperative toripalimab does not increase surgical complications, demonstrating safety comparable to chemotherapy alone.
Findings support integrating immune checkpoint inhibitors into multimodal treatment for locally advanced NSCLC to optimize surgical and long-term outcomes.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.